PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
August 07, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
August 06, 2024 08:00 ET
|
Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
July 16, 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024 07:00 ET
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
July 08, 2024 16:05 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Forbion Strengthens US Presence, Hiring Biotech Industry Leader and Opening Boston Office
June 27, 2024 07:00 ET
|
Forbion
Josh Brumm, previously CEO of Dyne Therapeutics, appointed as General Partner at Forbion. Brumm to be located at Forbion's new Boston office.
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
WellSpan Health Partners with Jersey College to Establish a Dedicated School of Nursing in South Central Pennsylvania
June 11, 2024 09:41 ET
|
WellSpan Health
York, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- WellSpan Health and Jersey College, an accredited post-secondary institution specializing in nursing education, have received regulatory approval to...